There are no approved vaccines for HSV, and GSK’s decision to stop developing ... an investigational vaccine for herpes ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...
Hosted on MSN2mon
It’s rarely lethal, but genital herpes costs the world $35 billion a year and 20% of people have itSymptomatic HSV-2 infection is also associated with an ... and therapeutics that reduce severity and viral load. Another company, GSK, completed a vaccine trial in September 2024, but the vaccine ...
Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD-2) was effective in protecting HSV-1/HSV-2-seronegative women whose sexual partners had recurrent HSV ...
GSK is also working with SK Bioscience on a phase 1/2 study for a vaccine based on self-assembling nanoparticle technology developed by the University of Washington, with funding from CEPI and the ...
GSK blames political and regulatory pressures ... with Zhifei now set to purchase 21.6bn yuan ($2.97bn) worth of the vaccine over six years. The revision follows a sharp downturn in China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback